Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 21, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

July 7, 2019

Conditions
Cannabis Use Disorder
Interventions
DRUG

Ondansetron 8mg

Ondansetron 8 MG prepared in a 100 mL normal saline min-bag

DRUG

Haloperidol 0.05mg/kg

Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag

DRUG

Haloperidol 0.1mg/kg

Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag

Trial Locations (3)

K7L 2V7

Hotel Dieu Hospital, Kingston

Kingston General Hospital, Kingston

K7L 3N6

Queen's University, Kingston

All Listed Sponsors
lead

Dr. Marco L.A. Sivilotti

OTHER

NCT03056482 - Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) | Biotech Hunter | Biotech Hunter